| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_79c86d2d9edaa7cdf46ed1c241194b86
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_43a72884e25aaecffebe0942132d704f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_df02dc2eab1779ebc7dfb5accf94318b |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-352
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-497
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-225
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-277
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-12 |
| filingDate |
2019-11-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_216c5280477c9a687db2fc9e7d1382e1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_be0100c823a91e609dc2913f30223f6a |
| publicationDate |
2020-05-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2020094767-A1 |
| titleOfInvention |
Use of nrf2 activators for the treatment of staphylococcus aureus infections |
| abstract |
Staphylococcus aureus infection affects immune and inflammatory host responses causing severe bacterial infections and complicated antibiotic therapy. As important actors of the innate immune defenses, macrophages are actively involved in the microbial elimination and their active states are sensitive to the microenvironment. In this study, the inventors investigate the impact of Nuclear factor erythroid 2-related factor 2 (Nrf2) activation on the intracellular bacterial load in macrophages and the underlying molecular mechanisms involved in this process. THP1-derived macrophages pretreated with Nrf2 activator sulforaphane (SFN) significantly reduce bacterial internalization and intracellular bacterial survival when challenged with S. aureus. Accordingly, the present invention relates to a method of treating a Staphylococcus aureus infection in a patient in need thereof comprising administering to the patient a therapeutically effective amount of a Nrf2 activator. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-114886902-A |
| priorityDate |
2018-11-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |